SLEEP 2025: Analyzing High-Level, Late-Breaking Data

In this episode, Eric Olson, MD, and Anita Shelgikar, MD, review the XYLO study’s findings on the impact of switching from high- to low-sodium oxybate on blood pressure in patients with narcolepsy.

Panelists Eric Olson, MD, and Anita Shelgikar, MD, examine interim data on high-dose low-sodium oxybate in patients with narcolepsy, discussing safety signals, efficacy trends, and clinical considerations. [WATCH TIME: 4 minutes]

In episode 3, Drs. Olson and Shelgikar break down a retrospective study exploring how social determinants of health impact the clinical experience of patients with narcolepsy. [WATCH TIME: 6 minutes]

In this segment, Eric Olson, MD, and Anita Shelgikar, MD, discuss the design of the Vibrance-3 trial, a phase 2 study of the orexin-2 receptor agonist ALKS 2680 in patients with idiopathic hypersomnia. [WATCH TIME: 4 minutes]

In episode 5, the sleep specialists examine actigraphy data from a study of TAK-861 in narcolepsy type 1 and discuss the promise of home-based sleep tracking in clinical care. [WATCH TIME: 3 minutes]

In this final episode, the sleep experts analyze real-world prescribing data to understand how low-sodium oxybate impacts the use of traditional alerting agents in narcolepsy. [WATCH TIME: 4 minutes]